ROCO
4132
Market cap65mUSD
May 15, Last price
13.85TWD
1D
2.18%
1Q
-12.19%
Jan 2017
-70.17%
IPO
-59.56%
Name
Golden Biotechnology Corp
Chart & Performance
P/E
—
P/S
31.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-7.08%
Revenues
63m
-70.88%
Net income
-362m
L+33.02%
CFO
-271m
L+10.33%
Profile
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 63,429 -70.88% | 217,825 166.39% | |||
Cost of revenue | 429,011 | 514,594 | |||
Unusual Expense (Income) | |||||
NOPBT | (365,582) | (296,769) | |||
NOPBT Margin | |||||
Operating Taxes | 293 | 116 | |||
Tax Rate | |||||
NOPAT | (365,875) | (296,885) | |||
Net income | (361,642) 33.02% | (271,877) -38.74% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | 247,975 | 252,022 | |||
Long-term debt | 45,195 | 63,273 | |||
Deferred revenue | |||||
Other long-term liabilities | 2,248 | ||||
Net debt | 82,282 | (208,190) | |||
| Cash flow | |||||
Cash from operating activities | (271,316) | (245,903) | |||
CAPEX | (4,885) | (18,038) | |||
Cash from investing activities | (18,637) | 63,470 | |||
Cash from financing activities | (21,796) | (26,316) | |||
FCF | (305,279) | (313,397) | |||
| Balance | |||||
Cash | 210,888 | 523,485 | |||
Long term investments | |||||
Excess cash | 207,717 | 512,594 | |||
Stockholders' equity | 410,141 | 771,846 | |||
Invested Capital | 469,009 | 540,551 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 142,379 | 142,227 | |||
Price | 39.65 -33.92% | 60.00 -53.49% | |||
Market cap | 5,645,317 -33.85% | 8,533,620 -49.97% | |||
EV | 5,727,599 | 8,332,602 | |||
EBITDA | (314,554) | (245,567) | |||
EV/EBITDA | |||||
Interest | 6,731 | 4,075 | |||
Interest/NOPBT | |||||